摘要
采用美国生产肿瘤标志物（ＤＲ７０ＴＭ）试剂以免疫学酶联方法对１４种癌症３５０例患者和３３５例健康人进行对照检测，其结果表明：肺癌阳性率约为８８１％；胃癌为９２８５％；乳腺癌为６５６７％；肠癌为８３３３％；肝癌为９１８９％；卵巢癌为９３７５％；食道癌为９２８５％和宫颈癌为８７５０％等，总计癌症患者阳性率约为８２２８％，与健康对照组比较，Ｐ＜０００１，差异有高度显著性。认为ＤＲ７０ＴＭ试剂可作为辅助诊断及监测肿瘤复发的指标，为临床提供参考依据。
A clinical study using DR 70 TM immunoassay for the detection of 14 different kinds of cancer was conducted with 335 healthy subjects and 350 cancer patients.The test results showed that the DR 70 TM immunoassay kit was capable of detecting cancers with high degree of specificity and sensitivity,at 88.1%,92.85%,65.67%,83.33%,91.89%,93.75%,92.83%and 87.50% respectively for lung,stomach,breast,rectum,liver,ovary,esophagus and cervix.Furthermore,the test kit was shown to be stable and could be performed reproducibly.
关键词
肿瘤
诊断
肿瘤标记物
DR-70^TM
MeSH\ tumor markers,biological
enzyme linked immunosorbent assay
neoplasms/DI
